Janssen Pharmaceuticals

Parts of this article (those related to weighing public health concerns with Janssen vaccine's crucial role in health equity and mitigating spread of SARS-CoV-2 spread and resulting mutations) need to be updated. Please help update this article to reflect recent events or newly available information. (April 2021)

Johnson & Johnson Innovative Medicine

Company type	Subsidiary
Industry	Pharmaceutical
Founded	1953; 71 years ago (1953)
Founder	Paul Janssen
Headquarters	Turnhoutseweg 30, Beerse , Belgium
Area served	Worldwide
Key people	Jennifer Taubert
Number of employees	45.000
Parent	Johnson & Johnson
Website	www.janssen.com

Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

In 1961, Janssen Pharmaceuticals was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.